40 results about "Biogenesis" patented technology

Provided herein are methods of culturing cells in vitro in order to exploit the biochemical production ability of the cells to make metabolites that are evaluated and harvested for their biological effects. Also provided are systems for evaluating extracts from such cultured cells to characterize their biological activity(s), particularly with regard to impact on health, wellbeing, longevity, DNA maintenance, mitochondrial health and/or biogenesis, and so forth. Biologically active extracts, components thereof, and compositions (such as cosmetic or pharmaceutical preparations) made comprising such, are also provided.

Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

It is possible to inactivate the early stage of lipid A synthesis of mucosal gram negative bacteria without compromising cell viability. In particular the lpxA gene in N. meningitidis was mutated and resulting lpxA knockout mutants were found to be completely lipopolysaccharide (LPS)-deficient. The major outer membrane proteins (OMPs) were detected in normal amounts. The finding provides important implications for understanding of structure and biogenesis of the outer membrane. On a practical level, the availability of LPS-deficient mutants of pathogenic mucosal bacteria such as N. meningitidis opens up new avenues to vaccine development. It enables easy isolation of endotoxin-free purified proteins, outer membranes or even whole-cell preparations for use in immunisation.

Nutritional products, compositions, functional ingredients, medical foods, pharmaceutical preparations and methods of use are disclosed for support and improvement of athletic performance (strength, flexibility, endurance, balance, and conditioning), and prevention and repair of injuries, including improving or maintaining muscle mitochondrial health, stimulating muscle mitochondrial biogenesis as well as other indications as set forth herein. In addition, pharmaceutical, nutraceutical and nutritional medical food compositions that are useful in conditions, normal or abnormal, associated with mitochondrial dysfunction and altered biogenesis in organ systems consisting of skeletal muscle, smooth muscle and cardiac muscle are also disclosed. L-Ergothioneine (also referred to as Ergothioneine or ET), Vitamin D2 (Ergocalciferol) and/or other antioxidants are disclosed for use in pharmaceutical, nutraceutical and nutritional medical food compositions for uses to stimulate production of bioactive molecules, including but not limited to glutathione, alpha synuclein, and IL-6.

The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to stimulate mitochondrial function in cells. The methods and compositions described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia /reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.

The present invention relates to a composition comprising an autophagy enhancement compound. Small molecules that are able to enhance autophagy and lysosome biogenesis by activating the gene TFEB which can prevent the accumulation of toxic protein aggregates in treating neurodegenerative diseases are disclosed.

The invention discloses a club moss alkaloid compound or a pharmaceutical salt thereof represented by the structural formula (I) where R1 is hydrogen, aryl, substituted aryl, alkyl or substituted alkyl, R2 is hydrogen, hydroxyl or a halogen atom, R3 is hydrogen, aryl, substituted aryl, alkyl or substituted alkyl, R4 is hydrogen, hydroxyl or a halogen atom, and n is an integer from 0 to 4, as well as a preparation method of the club moss alkaloid compound, a medicine composition containing the compound of the type, a plant extract and application of the compound of the type, the medicine composition of the compound and the extract in preparation of an anticholinesterase inhibitor medicine, preparation of a medicine for treating the alzheimer's disease and preparation of a medicine for treating the memory and cognitive impairment diseases of middle-aged and old people. Club moss alkaloids are diversified natural alkaloids which are of similar and unique structures, separated from fern club moss and relative plants thereof, and have the same biogenesis.

A composition suitable for inhibiting the outgrowth of fungi is provided comprising a first ingredient which inhibits the biogenesis of a normal fungal cell wall and a second ingredient which is capable of perturbing the structure of the cellular membrane of said fungi, so that either the cellular integrity is essentially lost or cell division cannot take place, or both. The first ingredient preferably inhibits the anchorage of cell wall proteins in the cell wall of the fungi and is suitably a beta-(1,6)-glucose polysaccharide, preferably beta-gentiobiose or a pustulan fragment. The second ingredient is suitably a natural microbial membrane affecting substance (MMAS), preferably MB-21. The composition is particularly suitable as a preservative for inhibiting the outgrowth of fungi in food products, such as sauces, dressings, ketchups, and soups, but is also useful for preventing or inhibiting undesired fungal growth on other products such as personal health care products, e.g. soap bars.

A method and system are provided for the production of triterpene including methylated triterpenes. The method and system include isolated nucleic acid sequences encoding triterpene methyltransferases such as triterpene methyltransferases 1, 2, 3. Advantageously, the method and system includes transgenic plant cells via an expression vector for triterpene methyltransferase and optionally various triterpene synthase and prenyltransferase all with tags directing these enzymes to the chloroplast of the transgenic plant cells for using the chloroplast methyl erythritol phosphate (MEP) pathway in the triterpene biogenesis.

The molecular mechanisms of peroxisome biogenesis have begun to emerge: in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor. Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H₂O₂, and this increased load of reactive oxygen species (ROS) may further reduce peroxisomal protein import and exacerbate the effects of aging. Disclosed are novel compositions and methods for restoring catalase in peroxisomes by use of targeted catalase modified at its C-terminus and/or N-terminus, optionally in combination with polypeptides which promote cellular uptake of proteins, to prevent or overcome the changes that follows aging or that are associated with a number of diseases or disorders.

The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia-derived compounds, including malassezin and indirubin, and/or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating aylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.

The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia-derived compounds, including malassezin and indirubin, and/or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.

The present invention relates to a composition comprising an autophagy enhancement compound. Small molecules that are able to enhance autophagy and lysosome biogenesis by activating the gene TFEB which can prevent the accumulation of toxic protein aggregates in treating neurodegenerative diseases are disclosed.

The invention discloses a method for filtering, evolving and classifying proteome and a system thereof. The method comprises the following steps of: an original data acquiring step: acquiring the genome data and the proteome data (S110) of species to be classified; a predicting step: predicting a transversal transfer gene (S120) in a genome sequence based on the genome data; a filtering step: filtering a proteome sequence (S130) corresponding to the transversal transfer gene in the proteome based on the proteome data and the transversal transfer gene; a calculating step: calculating the evolving distance (S140) between the species with the filtered proteome sequence; and an inferring step: inferring a phylogeny relation (S150) between the species by utilizing the evolving distance between the species. According to the invention, existing interference information which is caused by transversal gene transfer during deducing a biogenesis process can be eliminated so that the deduced biogenesis process is more accurate to provide a more reliable classification basis for biological evolution and classification.

The invention relates to a new biogenesis oral solution and a preparation method thereof. Every 800-1200ml of oral solution is prepared from the following components by weight: 8000-12000mg of vitamin C, 6000-8500mg of vitamin B3, 800-1200mg of vitamin B1, 80-120mg of vitamin B2, 300-600mg of taurine, 2800-3200mg of lentinan, 1800-2200mg of zinc gluconate, 2800-3200mg of stevioside and the balance of pure water. The new biogenesis oral solution is prepared from vitamin C, vitamin B3, vitamin B1, vitamin B2, taurine, lentinan, zinc gluconate, stevioside and pure water in a fixed weight ratio, wherein the vitamin C, vitamin B3, vitamin B1, vitamin B2, taurine, lentinan, zinc gluconate and stevioside are necessary nutrition to a human body. The oral solution is simple and reasonable in raw material proportion, the effects of the raw materials are supplementary to each other, and the oral solution has the advantages of enhancing immunity, promoting growth and development, resisting oxidation and promoting food digestion.

A vaccine platform using a Yersinia pestis mutant synthesizing an adjuvant form lipid A (monophosphoryl lipid A, MPLA) for the increased biogenesis of bacterial outer membrane vesicles (OMVs). To enhance the immunogenicity of the OMVs, an Asd-based balanced-lethal host-vector system was constructed to oversynthesize the LcrV antigen of Y. pestis, raise the amounts of LcrV enclosed in OMVs by Type II secretion system, and eliminate harmful factors like plasminogen activator (Pla) and murine toxin from the OMVs. Vaccination with OMVs containing MPLA and increased amounts of LcrV with diminished toxicity afforded complete protection in mice against subcutaneous challenge and intranasal challenge and was significantly superior to that resulting from vaccination with LcrV/alhydrogel. Additionally, the Yersinia OMV can be used as a platform to deliver the heterologous antigens of Bacillus anthraces. Vaccination with multiantigenic self-adjuvanting bionanoparticles from Pseudomonas was also successfully tested in connection with Pseudomonas aeruginosa.

Provided is a method for identifying and reducing the risk of a female subject producing an offspring having a neurodevelopmental disorder. The method comprises detecting in the subject the presence of gut bacteria that promote Th17 cell biogenesis. If such bacteria are detected, the individual can be administered a therapy that inhibits the growth or Th17 cell biogenesis promoting activity of the bacteria, and/or reduces the activity of the Th17 cells in the gut.

The invention discloses application of a human sirt3 gene or a sirt3-like gene or a product thereof in stem cell differentiation inducing, and provides a method for promoting stem cell differentiationor mitochondrial biogenesis increase. The high-expression sirt3 protein can significantly enhance aerobic metabolism of stem cells and promote conversion of stem cell metabolism from glycolysis to oxidative phosphorylation; the sirt3 improves the biogenesis of stem cell mitochondria, and is beneficial to inducing stem cell differentiation. After the stem cells are induced and differentiated by the sirt3, the stem cells can be developed into various tissues and used for artificial organ regeneration, for example, bone marrow mesenchymal stem cells are differentiated into osteoblasts used for bone tissues for 3D printing.